Home › Modalities › Peptide
Peptide (21 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 8 | Phase 1 | $910M | 10 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 3 | Phase 3 | $298M | 3 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 3 | Phase 3 | $3.54B | 5 |
| BCYC | Bicycle Therapeutics | Oncology | 3 | Phase 2 | $224M | 4 |
| ELTX | Elicio Therapeutics | Oncology | 5 | Phase 2 | $40.5M | 6 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 4 | Phase 2 | $522M | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 1 | Approved | $1.84B | 17 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $274M | 1 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 4 | Phase 2 | $60.7M | 13 |
| MBX | MBX Biosciences | Metabolic Rare | 4 | Phase 3 | $2.64B | 4 |
| NGEN | NervGen Pharma | Neurology | 2 | Phase 3 | $211M | 3 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 | 5 | Phase 3 | $9.5M | 5 |
| PMN | ProMIS Neurosciences | Neurology Rare | 3 | Phase 1 | $28.9M | 9 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 10 | Approved | $8.14B | 12 |
| RNTX | Rein Therapeutics | Respiratory Rare | 1 | Phase 2 | $30.7M | 1 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 12 | Approved | $8.08B | 14 |
| SLS | SELLAS Life Sciences Group | Oncology | 5 | Phase 3 | $3.90B | 9 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | 2 | Approved | $53.9M | 4 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 4 | Phase 3 | $3.43B | 9 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 1 | Approved | $3.07B | 4 |
No companies match.